| |
| Item |
Topic |
Impact Factor |
| 1 |
Chou, H. H., Huang, H. J., Lin, H., Yang, L. Y., Hsueh, S., Liu, F. Y., Liou, Y. L., Liou, J. D., Chen, M. Y., Chao, A., Lin, G., Chang, T. C., and Lai, C. H. (2015). Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer. American Journal of Clinical Oncology: 40(3), 241-249. |
[SCI, IF=2.977] |
| 2 |
Wang, C. C., Chou, H. H., Yang, L. Y., Lin, H., Liou, W. S., Tseng, C. W., Liu, F. Y., Liou, J. D., Huang, K. G., Huang, H. J., Huang, E. Y., Chen, C. H., Chang, T. C., Chang, C. J., Hong, J. H., and Lai, C. H. (2015). A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: An Asian Gynecologic Oncology Group study. Gynecologic Oncology: 137(3), 462-467. |
[SCI, IF=3.774] |
| 3 |
Hong, H. H., Hong, A., Yang, L. Y., Chang, W. Y., Huang, Y. F. and Lin, Y. T. (2017). Implant Stability Quotients of Osteotome Bone Expansion and Conventional Drilling Technique for 4.1 mm Diameter Implant at Posterior Mandible. Clinical Implant Dentistry and Related Research: 19(2), 253-260. |
[SCI, IF=3.097] |
| 4 |
Tseng, J. R., Pang, S. T., Fan, K. H., Hong, J. H., Lin, P. H., Yang, L. Y., Chang, H. Y., Yang, H. T., Ng, K. F., Wang, L. J. and Yen, T. C. (2017). 11C-choline PET/MRI for characterization of primary high-risk prostate cancer: Correlations of PET imaging parameters with clinical features. Journal of Pharmacy and Pharmacology:7, 391-400. |
[SCI, IF=2.405] |
| 5 |
Wang, C. W., Yang, L. Y., Chen, C. B., Ho, H. C., Hung, S. I., Yang, C. H., Chang, C. J., Su, S. C., Hui, R. C. Y., Chin, S. W., Huang, L. F., Lin, Y. W., Chang, W. Y., Fan, W. L., Yang, C. Y., Ho, J. C., and Chung, W. H., Taiwan Severe Cutaneous Adverse Reaction Consortium. (2018). Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation.: 128(3): 985-996. |
[SCI, IF= 12.784] |
| 6 |
Lai, C.H., Vallikad, E., Lin, H. , Yang, L. Y., Jung, S.M., Liu, H.E., Ou, Y.C., Chou, H.H., Lin, C.T., Huang, H.J., Huang, K.G., Qiu, J.,Hung, Y.C., Wu, T.I., Chang, W.Y., Tan, K.T., Lin, C.Y., Chao, A., Chang, C.J. (2019) Maintenance of peylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group. Journal of Gynecologic Oncology: 2019;31:e5 |
[SCI, IF=2.914] |
| 7 |
Huang, Y.H., Chen, S.T., Liu, F.H., Hsieh, S.H., Lin, C.H., Liou, M.J., Wang, C.C., Huang, C.H., Liu, G.H., Lin, J.R., Yang, L. Y., Hsu, T.Y., Lee M.C., Huan,g C.T., Wu, Y.H.. (2019) The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: A randomized, double-blind, placebo-controlled pilot trial. PLoS One: 2019 Aug 15;14(8):e0221199. [SCI, IF=2.776] |
[SCI, IF=2.776] |
| 8 |
Chou, H. H., Chen, W. C., Yang, L. Y., Huang, H. J., Chang, W. Y., Lin, H., Wu, R. C., Chen, M. Y., Qiu, J., Huang, K. G., Chao, A., Chang, T. C., Lai, C. H. (2021). Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021 Apr 18;262:13-20.[SCI, IF=1.868] |
[SCI, IF=1.868] |
| 9 |
Chien, C. Y., Fang, S. Y., Tsai, L. H., Tsai, S. L., Chen, C. B., Seak, C. J., Weng, Y. M., Lin, C. C., Chien, W. C., Huang, C. H., Lin, C. Y., Chaou, C. H., Liu, P. H., Tseng, H. J., Chen, J. C., Peng, S. Y., Cheng, T. H., Hsu, K. H. and Ng, C. J. (2020). Traditional versus blended CPR training program: A randomized controlled non-inferiority study. Scientific Reports, 10(1), 10032. |
[SCI, IF=3.998] |
|
|
|
|